Vaccitech to Present at the Jefferies Healthcare Conference
June 06 2022 - 4:15PM
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines, today announced that the Company’s
Chief Executive Officer, Bill Enright, and Chief Financial Officer,
Georgy Egorov, will participate in a fireside chat at the Jefferies
Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8,
2022 in New York City.
A live webcast of the presentation can be
accessed through the Events section of the Vaccitech
website. Following the live webcast, a replay will be available at
the same location.
About Vaccitech plcVaccitech
(“the Company”) is a clinical-stage biopharmaceutical company
engaged in the discovery and development primarily of novel
immunotherapies for the treatment of chronic infectious diseases,
cancer, autoimmunity and diseases where the T cell arm of the
immune system is believed to play an important role. The company’s
proprietary platforms include modified simian adenoviral vectors
(ChAdOx1 and ChAdOx2), other viral vectors including the
well-validated Modified Vaccinia Ankara (MVA) and synthetic
nano-particle technologies (SNAPvax™ and Syntholytic™). The
combination of different technologies in a mix and match approach
(heterologous prime-boost) consistently generates significantly
higher magnitudes of T cells compared with other technologies and
approaches. The company has a broad pipeline of both clinical and
preclinical stage therapeutic programs to treat solid tumors,
chronic viral infections, as well as a few prophylactic viral
vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the
University of Oxford, now approved for use in many territories and
exclusively licensed worldwide to AstraZeneca through Oxford
University Innovation, or OUI. Vaccitech is entitled to receive a
share of all milestones and royalty income received by OUI from
AstraZeneca.
Vaccitech Media contacts:Katja
Stout, Scius Communications (EU)Direct: +44 (0)
7789435990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D., Burns
McClellan, Inc.
(U.S.)Email: klarch@burnsmc.com / rflamm@burnsmc.com
Georgy Egorov, CFO,
VaccitechEmail: IR@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Apr 2023 to Apr 2024